162 related articles for article (PubMed ID: 35612613)
1. Retinal vascular occlusion and SARS-CoV-2 vaccination.
Vujosevic S; Limoli C; Romano S; Vitale L; Villani E; Nucci P
Graefes Arch Clin Exp Ophthalmol; 2022 Nov; 260(11):3455-3464. PubMed ID: 35612613
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Branch Retinal Vein Occlusion Post-mRNA SARS-CoV-2 (COVID-19) Vaccination.
Lee J; Ong KW; Wan Abdul Halim WH; Mohd Khialdin S; Yong MH
Optom Vis Sci; 2023 Nov; 100(11):799-803. PubMed ID: 37844608
[TBL] [Abstract][Full Text] [Related]
3. Central retinal vein occlusion after mRNA SARS-CoV-2 vaccination: A case report.
Endo B; Bahamon S; Martínez-Pulgarín DF
Indian J Ophthalmol; 2021 Oct; 69(10):2865-2866. PubMed ID: 34571653
[TBL] [Abstract][Full Text] [Related]
4. Bilateral central retinal vein occlusion following COVID-19 vaccination: Cause or coincidence?
Matri KE; Werda S; Chebbi Z; Saidane R; Doukh M; Choura R; Falfoul Y; Limaiem R; Matri LE
Eur J Ophthalmol; 2024 May; 34(3):NP78-NP81. PubMed ID: 38291623
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
Kim M; Jeong S; Sagong M
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
[TBL] [Abstract][Full Text] [Related]
6. Retinal vascular occlusions in COVID-19 infection and vaccination: a literature review.
Yeo S; Kim H; Lee J; Yi J; Chung YR
Graefes Arch Clin Exp Ophthalmol; 2023 Jul; 261(7):1793-1808. PubMed ID: 36598554
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion.
Jaissle GB; Szurman P; Feltgen N; Spitzer B; Pielen A; Rehak M; Spital G; Heimann H; Meyer CH;
Graefes Arch Clin Exp Ophthalmol; 2011 Feb; 249(2):183-92. PubMed ID: 21337042
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
10. Vascular retinal findings after COVID-19 vaccination in 11 cases: a coincidence or consequence?
Silva LSCD; Finamor LPS; Andrade GC; Lima LH; Zett C; Muccioli C; Sarraf EP; Marinho PM; Peruchi J; Oliveira RDL; Giralt L; Charcan I; Fonollosa A; Diaz JD; Davis JL; Nascimento H; Belfort R
Arq Bras Oftalmol; 2022; 85(2):158-165. PubMed ID: 35298583
[TBL] [Abstract][Full Text] [Related]
11. OPTICAL COHERENCE TOMOGRAPHY PREDICTORS OF SHORT-TERM VISUAL ACUITY IN EYES WITH MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL CONBERCEPT.
Tang F; Qin X; Lu J; Song P; Li M; Ma X
Retina; 2020 Apr; 40(4):773-785. PubMed ID: 30640282
[TBL] [Abstract][Full Text] [Related]
12. Branch retinal artery occlusion with unruptured retinal arterial macroaneurysm post-SARS-CoV-2 vaccination: A case report.
Murata K; Nagasato D; Tanaka H; Nakakura S; Nagasawa T; Mitamura Y; Tabuchi H
Eur J Ophthalmol; 2024 May; 34(3):NP53-NP56. PubMed ID: 37941398
[TBL] [Abstract][Full Text] [Related]
13. CENTRAL RETINAL VEIN OCCLUSION FOLLOWING BNT162B2 (PFIZER-BIONTECH) COVID-19 MESSENGER RNA VACCINE.
Shah PP; Gelnick S; Jonisch J; Verma R
Retin Cases Brief Rep; 2023 Jul; 17(4):441-444. PubMed ID: 35025191
[TBL] [Abstract][Full Text] [Related]
14. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.
Januschowski K; Feltgen N; Pielen A; Spitzer B; Rehak M; Spital G; Dimopoulos S; ; Meyer CH; Szurman GB
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):457-462. PubMed ID: 27632214
[TBL] [Abstract][Full Text] [Related]
16. "Off-label" use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions.
Dascalu AM; Popa-Cherecheanu A; Popa-Cherecheanu M; Nica A; Serban D
Rom J Ophthalmol; 2016; 60(2):90-95. PubMed ID: 29450329
[TBL] [Abstract][Full Text] [Related]
17. SD-OCT pattern of retinal venous occlusion with cystoid macular edema treated with Ozurdex®.
Coscas G; Coscas F; Zucchiatti I; Glacet-Bernard A; Soubrane G; Souïed E
Eur J Ophthalmol; 2011; 21(5):631-6. PubMed ID: 21500185
[TBL] [Abstract][Full Text] [Related]
18. The impact of delayed anti-vascular endothelial growth factor treatment for retinal diseases during the COVID-19 lockdown.
Bulut MN; Sönmez HS; Gökçe G; Ağaçkesen A; Bulut K; Hacısalihoğlu A; Arsan A; Şimşek Ş
Photodiagnosis Photodyn Ther; 2021 Sep; 35():102449. PubMed ID: 34314862
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
Ehlers JP; Decroos FC; Fekrat S
Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
